Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 8/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24316481 | 0.93 | LPL (0.43) | LPLLIPGIRAK4HIF1AROCK1 | |
| SCHEMBL24316495 | 0.93 | LPL (0.46) | LPLLIPGIRAK4HIF1AROCK1 | |
| SCHEMBL24316498 | 0.90 | LPL (0.41) | LPLLIPGIRAK4HIF1AROCK1 | |
| SCHEMBL22797188 | 0.89 | LPL (0.39) | LPLLIPGIRAK4HIF1AROCK1 | |
| SCHEMBL25818754 | 0.85 | LPL (0.35) | LPLLIPGHIF1AROCK1PRMT5 | |
| SCHEMBL25035907 | 0.84 | LPL (0.40) | LPLLIPGIRAK4PRMT5WDR77 | |
| SCHEMBL22797496 | 0.84 | LPL (0.39) | LPLLIPGIRAK4HIF1AROCK1 | |
| SCHEMBL25896413 | 0.84 | LPL (0.39) | LPLLIPGIRAK4HIF1AROCK1 | |
| SCHEMBL25038278 | 0.84 | LPL (0.39) | LPLLIPGIRAK4 | |
| SCHEMBL24316681 | 0.83 | LPL (0.39) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11800792-B2 | Organic compound with spirocyclic adamantane, and electronic element and electronic device using same | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-10-24 | — | — | US | disclosed |
| US-11800792-B2 | Organic compound with spirocyclic adamantane, and electronic element and electronic device using same | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-10-24 | — | — | US | disclosed |
| US-11691952-B2 | Nitrogen-containing compound, and electronic element and electronic device using same | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-11691952-B2 | Nitrogen-containing compound, and electronic element and electronic device using same | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-20230200215-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230200215-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230052660-A1 | NITROGEN-CONTAINING COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-02-16 | — | — | US | disclosed |
| WO-2022068292-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | 陕西莱特光电材料股份有限公司 | 2022-04-07 | — | — | WO | disclosed |
| US-9585884-B2 | Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11800792-B2 | Organic compound with spirocyclic adamantane, and electronic element and electronic device using same | OR51E2, SQLE, ODC1 | LPL 1537/4885LIPG 1068/4885IRAK4 1726/4885 |
| US-20230052660-A1 | NITROGEN-CONTAINING COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | NOD1, NFE2L2, NOTCH1 | LPL 4283/4885LIPG 2238/4885IRAK4 3858/4885 |
| US-20230200215-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | LEF1, OCIAD1, OR10J3 | LPL 719/4885LIPG 461/4885IRAK4 1998/4885 |
| US-11691952-B2 | Nitrogen-containing compound, and electronic element and electronic device using same | NOD1, NFE2L2, NOTCH1 | LPL 4283/4885LIPG 2238/4885IRAK4 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.